Clinical Trial Update: Intratumoral Extracellular Metabolic Impact of DFMO and AMXT 1501 in Patients With Diffuse or High Grade Glioma [EARLY_Phase 1]

View source ↗

Summary

Early-phase trial evaluating the intratumoral metabolic impact of DFMO combined with AMXT-1501 in patients with diffuse or high-grade glioma; recruitment is ong…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Glioma
• High-grade Glioma
• Malignant Glioma

Drugs mentioned

• AMXT 1501 (AMXT-1501)
• DFMO (difluoromethylornithine)

Snippet

Sponsor: Mayo Clinic | Conditions: Diffuse Glioma, Malignant Glioma | EARLY_Phase 1 | Status: RECRUITING